Treatment of Refractory Oral Erosive Lichen Planus with Topical Rapamycin: 7 Cases

被引:36
作者
Soria, A. [1 ]
Agbo-Godeau, S. [2 ]
Taieb, A. [3 ]
Frances, C. [1 ]
机构
[1] Hop Tenon, Serv Dermatol Allergol, FR-75020 Paris, France
[2] Hop La Pitie Salpetriere, Serv Stomatol, Paris, France
[3] Hop St Andre, Serv Dermatol, Bordeaux, France
关键词
Erosive lichen planus; Topical rapamycin; RENAL-TRANSPLANT RECIPIENTS; TRIAMCINOLONE ACETONIDE; TACROLIMUS; SIROLIMUS; CANCER; CYCLOSPORINE; MANAGEMENT; EFFICACY; TRIAL;
D O I
10.1159/000172830
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Chronic erosive oral lichen planus (CEOLP) is a painful disease. Topical steroids constitute the mainstay of treatment. Given the reports of a slightly greater risk of squamous-cell carcinoma, rapamycin may be a good candidate for recalcitrant CEOLP, as it has both immunosuppressive and antitumour properties. Objectives: To investigate the therapeutic effect and evaluate the blood absorption of topical rapamycin in patients with CEOLP. Patients and Methods: We carried out an open prospective study: 7 women with CEOLP applied topical rapamycin (1 mg/ml) on oral erosive lesions twice a day for 3 months. Four patients also had erosive vulvar lesions and applied the same solution on both mucosae. We monitored blood sirolimus levels 15 days after the initiation of treatment. Complete remission was defined by the disappearance of oral erosions and partial remission when the surface of oral erosions was 50% less than the surface of the initial erosion. Results: At 3 months, 4 women had complete remission and 2 women had partial remission. One patient stopped treatment due to local discomfort. Only 1 woman had blood sirolimus levels that were detectable. Conclusion: Topical rapamycin may be effective in some cases of refractory CEOLP, with negligible absorption into blood and minimal side effects. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:22 / 25
页数:4
相关论文
共 17 条
[1]  
Byrd, 2005, ARCH DERMATOL, V141, P370
[2]   Response of oral lichen planus to topical tacrolimus in 37 patients [J].
Byrd, JA ;
Davis, MDP ;
Bruce, AJ ;
Drage, LA ;
Rogers, RS .
ARCHIVES OF DERMATOLOGY, 2004, 140 (12) :1508-1512
[3]   The efficacy of aloe vera gel in the treatment of oral lichen planus: a randomized controlled trial [J].
Choonhakarn, C. ;
Busaracome, P. ;
Sripanidkulchai, B. ;
Sarakarn, P. .
BRITISH JOURNAL OF DERMATOLOGY, 2008, 158 (03) :573-577
[4]   Ciclosporin vs. clobetasol in the topical management of atrophic and erosive oral lichen planus: a double-blind, randomized controlled trial [J].
Conrotto, D ;
Carbone, M ;
Carrozzo, M ;
Arduino, P ;
Broccoletti, R ;
Pentenero, M ;
Gandolfo, S .
BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (01) :139-145
[5]   THE THERAPY OF ORAL LICHEN-PLANUS [J].
EISEN, D .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :141-158
[6]   Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population [J].
Gandolfo, S ;
Richiardi, L ;
Carrozzo, M ;
Broccoletti, R ;
Carbone, M ;
Pagano, M ;
Vestita, C ;
Rosso, S ;
Merletti, F .
ORAL ONCOLOGY, 2004, 40 (01) :77-83
[7]   Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months [J].
Gonwa, T ;
Mendez, R ;
Yang, HC ;
Weinstein, S ;
Jensik, S ;
Steinberg, S .
TRANSPLANTATION, 2003, 75 (08) :1213-1220
[8]   Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation [J].
Guba, M ;
Graeb, C ;
Jauch, KW ;
Geissler, EK .
TRANSPLANTATION, 2004, 77 (12) :1777-1782
[9]   Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection [J].
Holt, DW ;
Lee, T ;
Johnston, A .
CLINICAL THERAPEUTICS, 2000, 22 :B38-B48
[10]   Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus [J].
Kaliakatsou, F ;
Hodgson, TA ;
Lewsey, JD ;
Hegarty, AM ;
Murphy, AG ;
Porter, SR .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (01) :35-41